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Journal of Thoracic OncThe Importance of Accurate Lymph Node Staging in
Early and Locally Advanced Non-small Cell Lung
Cancer: An Update on Available TechniquesEdward S. Kim, MD, and Lionel Bosque´e, MDyAbstract: Medical oncologists are faced with multiple factors to
consider when staging a patient with suspected or confirmed non-
small cell lung cancer (NSCLC). Identifying pathological nodal
(N2) disease is, however, of great importance because its presence
significantly affects outcomes and potential treatment strategies.
Recent data supporting the use of adjuvant or neoadjuvant therapies
in these patients suggests that every reasonable effort should be
made to assess the lymph node status accurately in patients with
clinical early stage disease as well as in those with clinically staged
N2 disease who have undergone preoperative treatments. Newer
procedures such as integrated positron emission tomography com-
puted tomography and esophageal or endobronchial endoscopic
ultrasound with fine needle aspiration are minimally invasive
techniques that may enhance the accuracy of mediastinal staging,
traditionally devoted to mediastinoscopy. As their availability
widens, they are likely to become an important part of staging
and treatment paradigms. Intraoperatively, a growing body of
evidence suggests that lymph node dissection can be performed
safely, and should replace sampling as a more effective means of
identifying unsuspected N2 disease. This paper will review the
current literature on staging NSCLC with regard to the detection of
nodal disease through preoperative staging of the mediastinum, the
use of intraoperative lymph node sampling or dissection at the time
of resection, and procedures for use in restaging patients with
clinical stage IIIA N2 disease who have undergone preoperative
chemotherapy (with or without radiotherapy).
Key Words: Non-small cell lung cancer, Staging, Lymph
node, Preoperative, Intraoperative, Techniques.
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The accurate determination of disease stage in non-smallcell lung cancer (NSCLC) is important because of
the associated therapeutic and prognostic implications. A
careful initial diagnostic evaluation to define the location
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ology * Volume 2, Number 6, Supplemeninvolvement is critical for the appropriate care of patients.
Most critically, staging determines the candidacy for
potentially curative resection. The rate of futile thoraco-
tomies resulting from inaccurate preoperative staging has
been reported to be approximately 40%.1,2
Initial clinical staging is based on a combination of both
clinical factors (such as physical examination, radiological
tests, and laboratory studies) and pathological evaluation
obtained before resection (tumor and lymph node biopsies
obtained through various means). True pathological staging
can, however, only be performed at the time of resection. A
distinction between the clinical stage and the true
pathological stage should be considered when evaluating
reports of survival outcome, as prognosis varies between
these two types of staging (Table 1).3
This article will focus on lymph node staging, the
procedures for which can be divided into non-invasive and
invasive strategies. Invasive techniques are further sub-
divided into surgical and non-surgical procedures. These
strategies, along with the abbreviations that will be used in
this article are listed in Table 2. Several clinical practice
guidelines are available that offer advice to the practising
oncologist on how to navigate these choices.4–7 Although
these guidelines agree that an initial clinical work-up should
include computed tomography (CT), subsequent staging,
particularly of the mediastinum, is not as clearly defined. In
addition, newer staging procedures, including esophageal–
endoscopic ultrasound with fine needle aspiration
(EUS–FNA), endobronchial ultrasound with transbronchial
needle aspiration (EBUS–TBNA), video-assisted medias-
tinoscopic lymphadenectomy or transcervical extended
mediastinal lymphadenectomy (TEMLA), for example,
are becoming available, but are not universally applied. A
wide spectrum of factors must be considered when
determining the appropriate tests to assess the lymph nodes
in NSCLC, which includes not only the sensitivity and
specificity of the test, but the ability to perform the
procedure on an individual patient (inpatient versus
outpatient and whether it is scheduled together with
the primary tumor resection), the morbidity of the
procedure, the surgical expertise required, the accessibility
of the presumptive tumor locations and suspicious
nodes, the requirement for general anesthesia, and in the
case of mediastinoscopy, whether the procedure can be
repeated.uthorized reproduction of this article is prohibited.
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TABLE 1. Five-year Survival from Time of Surgery in Non-small Cell Lung Cancer.
Stage Clinical, % Pathological, %
Early Stage IA (T1 N0 M0) 61 67
IB (T2 N0 M0) 38 57
IIA (T1 N1 M0) 34 55
IIB (T2 N1 M0, T3 N0M) 22–24 38–39
Stage III IIIA (T3 N0–2 M0, T1–3 N2 M0) 9–13 23–25
IIIB (T4 N0–2 M0, T1–3 N3 M0) 3–7 NA
Kim and Bosque´e Journal of Thoracic Oncology * Volume 2, Number 6, Supplement 2, June 2007Stage III disease is particularly challenging because it
encompasses a heterogeneous group of tumors for which
management strategies are still controversial. Many patients
with stage III tumors are borderline resectable, and thus the
roles of preoperative chemotherapy or combined modality
treatment are yet to be defined (Figure 1). It is, however,
clear that because the presence of N2 disease may preclude
operability, or because preoperative treatment may be
required before resection, accurate preoperative staging of
the mediastinum is imperative to providing appropriate care
to these patients. Whereas non-invasive procedures are
preferable, CT alone is not optimal to detect N2 disease. In
the Z0050 trial of the American College of Surgeons
Oncology Group (ACOSOG), only 32% of patients with
pathologically confirmed N2/N3 disease were correctly
staged by non-invasive means (CT).8
Many studies have now documented the survival
advantages of either postoperative adjuvant chemotherapy
or neoadjuvant chemotherapy (with or without radiotherapy)
for patients with stage III N2 disease. In the large
prospective Adjuvant Navelbine International Trialist
Association (ANITA) trial of adjuvant chemotherapy,9
5-year survival for patients with stage III N2 disease who
received radiation was 47% after adjuvant cisplatin–
vinorelbine chemotherapy compared with 21% after
observation alone following surgery. In a smaller study,10,11
an impressive median survival of 28 months was found in a
phase II trial of neoadjuvant cisplatin–docetaxel. Sixty
percent of patients in that study were downstaged with
chemotherapy to pN0/N1, a significant factor associated
with long-term survival. This neoadjuvant combination withCopyright © Adis Data Information BV. Una
TABLE 2. Lymph Node Staging Procedures.
Non-invasive
Computed tomography (CT)
Magnetic resonance imaging (MRI)
18F-fluoro-deoxy-D-glucose positron
emission tomography scan (PET)
Integrated positron emission–computed
tomography (PET–CT)
S60radiation is currently being evaluated in phase III trials.12,13
These clinical data establish the fact that determining the
presence of N2 disease, whether it be preoperatively,
intraoperatively, or after neoadjuvant therapy is imperative
to providing optimal care to patients with pathological stage
IIIA disease. This paper will review current literature on
staging NSCLC with regard to the detection of N2 disease
through preoperative staging of the mediastinum, the use of
intraoperative lymph node sampling or dissection at the time
of resection, and procedures to use in restaging patients with
clinical stage III N2 disease who have undergone
preoperative chemotherapy (with or without radiotherapy).
STAGING THE MEDIASTINUM
From a safety standpoint, non-invasive techniques are
preferred to invasive techniques in staging the mediastinum.
It is also well established that accuracy suffers when using
non-invasive measures alone. When to use an invasive
technique has not been well defined. For example, would
mediastinoscopy be performed routinely in a patient with a
peripheral stage I, T1 tumor? Should it be performed
routinely in any stage patient or used only to confirm
suspicious nodes on imaging? The use of integrated positron
emission tomography (PET)–CT is improving the ability to
define suspicious nodes non-invasively. Newer minimally
invasive techniques such as EUS–FNA or EBUS–TBNA
are also changing the paradigm for invasive staging.
Non-Invasive Methods
PET imaging is superior to chest CT for detect-
ing mediastinal lymph node metastases. Results from authorized reproduction of this article is prohibited.
Invasive
Non-Surgical
Esophageal endoscopic ultrasound with fine
needle aspiration (EUS–FNA)
Endobronchial ultrasound with transbronchial
needle aspiration (EBUS–TBNA)
Transbronchial needle aspiration (TBNA)
Pleuroscopy
Surgical
Mediastinoscopy
Video-assisted mediastinoscopic lymphadenectomy (VAMLA)
Transcervical extended mediastinal lymphadenectomy (TEMLA)
Anterior mediastinotomy (Chamberlain procedure)
Video-assisted thoracic surgery (VATS)
 2007 International Association for the Study of Lung Cancer
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FIGURE 1. A treatment decision tree for patients with N2
disease.
Journal of Thoracic Oncology * Volume 2, Number 6, Supplement 2, June 2007 Importance of Accurate Lymph Node Stagingmeta-analysis by Toloza et al.14 demonstrated that when
compared with CT, PET has greater sensitivity (84 versus
57%), specificity (89 versus 82%), positive predictive value
(79 versus 56%), and negative predictive value (93 versus
83%), based on pooled results from the analysed trials.
Further evidence comes from the Z0050 trial of the
ACOSOG.8 In that trial, PET was performed in 303 eligible
patients considered to be surgical candidates (stages I–IIIA)
after standard imaging procedures (which included CT of
the chest and upper abdomen, bone scintigraphy, and
contrast-enhanced CT or magnetic resonance imaging
[MRI] of the brain). Looking specifically at nodal status,
the correct classification of N1 or N2/N3 disease was
statistically significantly more frequent with PET compared
with CT. For N1 disease, correct classification with PET and
CT, respectively, occurred in 42 and 13% of cases
( p¼ 0.02). For N2/N3 disease, corresponding values were
58% with PET and 32% with CT ( p¼ 0.004). In that study,
the sensitivity of PET to detect N2/N3 disease was 61%
compared with 37% with CT. As a result of the collective
data, PET is now considered the gold standard for initial
non-invasive mediastinal staging.
Nonetheless, whether the very early stage patient
requires PET is still not well defined. A retrospective study
evaluated whether PET standardized uptake value (SUV) of
the primary lesion, independent of size, correlates with the
presence of nodal or distant metastases at the time ofCopyright © Adis Data Information BV. Una
TABLE 3. Efficacy of Integrated Positron Emission–Comput
Undergoing Preoperative Staging.20
Nodal Stations
Sensitivity
(%)
Specificity
(%)
Po
2R, 2L 86 99
4L, 4R 96 91
6 62 94
5 78 97
7 75 91
8, 9 50 99
FN, False negatives; FP, false positives; TN, true negatives; TP, true positiv
(TNþFN); positive predictive value TP/(TPþFP); sensitivity TP/(TPþFN
 2007 International Association for the Study of Lung Cancerpresentation.15 This theory is based on the fact that various
studies have suggested that the magnitude of SUV with PET
inversely correlates with survival.16–18 In multivariate
analysis, SUV was a significant predictor of advanced
disease at presentation ( p¼ 0.04).15 The model in that study
suggests that an SUV of 7 corresponds to a 50% or greater
chance of having nodal or distant disease. If these findings
can be validated through prospective evaluation, then
perhaps targeted evaluation may make sense. For example,
utilizing additional means to identify metastatic disease
(e.g. MRI, mediastinoscopy) in a subgroup of patients with
elevated SUV in the primary tumor might be a feasible
option.
More recently, evaluations of integrated PET–CT
have suggested that this technology is superior to PET
alone. Evaluating either the tumor stage (n¼ 40) or the
nodal stage (n¼ 37), Lardinois and colleagues19 demon-
strated that PET–CT is particularly effective at improving
tumor staging compared with PET alone. Integrated
PET–CT correctly identified the tumor stage in 88% of
patients compared with 40% with PET alone. Although
the correct stage was identified with PET in an additional
40% of patients (as well as 10% with PET–CT), staging in
these patients was deemed equivocal. With respect to nodal
staging, PET–CT correctly identified the stage in 81% of
patients compared with 49% with PET alone; an additional
38% were correct but equivocal with PET and 3% with
PET–CT. Overall, integrated PET–CT was statistically
significantly more accurate at identifying both tumor and
nodal staging than PET alone ( p 0.013). It should also be
noted that integrated PET–CT was more accurate than the
visual correlation of PET and CT for tumor staging
( p¼ 0.013), although not for nodal staging. In a study that
evaluated the efficacy of clinical staging with integrated
PET–CT, as well as complementary methods, Cerfolio and
colleagues20 determined the efficacy parameters for
integrated PET–CT at the individual nodal stations in
383 patients presenting to the University of Alabama
(Table 3). A comparison of the efficacy of integrated
PET–CT versus PET at specific nodal stations was
performed at the same center in 129 patients.21 Integrated
PET–CT was statistically superior for all N2 stations as a
group in sensitivity, specificity, positive predictive value,uthorized reproduction of this article is prohibited.
ed Tomography for Each N2 Nodal Station in 383 Patients
sitive Predictive
Value (%)
Negative Predictive
Value (%)
Accuracy
(%)
94 98 98
62 99 93
31 98 92
36 97 94
61 95 89
40 99 97
es. Accuracy TPþTN/(TNþFNþTPþFP); negative predictive value TN/
); specificity TN/(TNþFP).
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TABLE 4. Individual Nodal Stations at which Sensitivity
and Positive Predictive Value Differed Significantly
( p0.05) between Integrated Positron Emission
Tomography–Computed Tomography and Dedicated
Positron Emission Tomography in Preoperative Staging of
129 Patients.21
Nodal Station
Sensitivity (%)
Positive Predictive
Value (%)
PET–CT PET PET–CT PET
2R 75 50
4R 100 86 70 55
4L 40 18
5 100 25 50 25
7 50 20 40 20
10L 100 40 39 14
11 100 40 71 29
CT, Computed tomography; PET, positron emission tomography; PET–
CT, integrated PET and CT.
FIGURE 2. Shaded areas indicate the nodal stations
within the reach of mediastinoscopy.
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sensitivity, specificity, positive predictive value, negative
predictive value, and accuracy. The specific nodal stations
for which statistical superiority was observed with
integrated PET–CT compared with PET in sensitivity and
positive predictive value are detailed in Table 4. Impor-
tantly, PET–CT had greater sensitivity and positive
predictive value at nodal stations 5 and 7. Nonetheless,
integrated PET–CT is not failsafe, and its usefulness lies in
its greater ability to identify areas for further testing
with biopsy.
Invasive Methods
Mediastinoscopy remains the standard confirmatory
procedure for suspicious nodes identified with CT or PET. A
number of mediastinal nodal stations are, however, not
accessible with this modality (Figure 2). This drawback
leaves the potential for undetected N2 disease. Although
performing mediastinoscopy with video-assisted mediasti-
noscopic lymphadenectomy improves the yield of lymph
nodes removed at most accessible stations, the specific
stations explored remains the same as in conventional
mediastinoscopy.22–24 Other procedures (e.g. anterior
mediastinotomy, pleuroscopy) may be used in concert
with mediastinoscopy, thus expanding the number of
stations explored. Using the newer TEMLA procedure,
additional stations (1, 3A, 5, 6, and 8) can also be
accessed.25,26 In a study of 41 patients, the sensitivity and
negative predictive value were improved with TEMLA
compared with standard (cervical) mediastinoscopy
(sensitivity 100 versus 37.5%; negative predictive value
100 versus 66.7%, respectively).26 Although postoperative
complications were not significantly different between
the two methods, pain intensity was statistically significantly
greater with TEMLA. Nevertheless, all mediastinoscopic
procedures require surgical intervention.Copyright © Adis Data Information BV. Una
S62Less invasive procedures have been studied that may
improve the detection of N2 disease beyond that of standard
mediastinoscopy. EUS–FNA is, among others, a minimally
invasive procedure that recent evidence suggests may be
useful. Whether adding EUS–FNA to mediastinoscopy
would improve staging was assessed in 100 patients with
confirmed NSCLC deemed resectable.27 Mediastinal tumor
invasion (T4) or lymph node metastases (N2/N3) were
identified in a greater percentage of patients undergoing
both procedures compared with either procedure alone
(36% EUS–FNA plus mediastinoscopy versus 20%
mediastinoscopy alone and 28% EUS–FNA alone). Sixteen
per cent of thoracotomies could thus have been avoided by
using EUS–FNA in addition to mediastinoscopy. Disease
detected by adding EUS–FNA was N2 metastasis in 9%, T4
tumor invasion in 4%, and both (N2 and T4) in 3% of
patients. Two per cent of EUS–FNA results were, however,
false positives. In two patients, lymph nodes located
immediately adjacent to the primary tumor were mistakenly
judged to be malignant, when in fact the sample had been
taken from the tumor instead. As such, the authors
recommend mediastinoscopy rather than EUS–FNA for
evaluating lymph nodes adjacent to the primary tumor.
A randomized trial in Denmark28 found that futile
thoracotomies could be prevented by using EUS–FNA up
front in all patients rather then reserving it for those with
enlarged nodes in the EUS–FNA-accessible regions on CT.
Patients with suspected or newly diagnosed NSCLC who
were candidates for invasive staging before resection
were randomly assigned to either conventional work-up
(EUS–FNA in selected patients; n¼ 51) or routine
EUS–FNA (n¼ 53). All patients underwent mediastino-
scopy unless contraindicated. The percentage of futileuthorized reproduction of this article is prohibited.
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with conventional work-up ( p¼ 0.03).
The addition of EUS–FNA appears to be particularly
useful for nodal stations 5, 8, and 9, as these are stations that
are inaccessible by mediastinoscopy, along with station 7, in
which the sensitivity and positive predictive value of
integrated PET–CT were found lacking in the study at the
University of Alabama (Table 3).20 In that study of
383 patients who underwent both integrated PET–CT and
CT, the incidence of unsuspected N2 disease was evaluated.
After PET–CT and CT, patients with suspicious nodes at the
2R/2L and 4R/4L levels were assessed by mediastinoscopy.
Those with suspicious nodes at stations 5, 7, 8, and 9 were
assessed by EUS–FNA. A total of 28 patients (14%) had
unsuspected N2 disease based on initial PET–CT and CT.
The highest percentage of unsuspected disease occurred in
the 50 clinical stage II patients (28% compared with 8.6% of
clinical stage I patients, and < 1% of clinical stage III or IV
patients). The most common location for unsuspected
disease was in the posterior mediastinal nodes (those
accessible by EUS–FNA). In clinical stage II patients, 86%
of those with unsuspected N2 disease had metastasis in the
posterior mediastinal nodes. The same investigators also
evaluated the positive predictive value and accuracy
of EUS–FNA compared with standard PET or CT in
104 patients who specifically presented with suspicious
nodes at stations 5, 7, 8, or 9 by these imaging methods.29
The positive predictive value (95% confidence interval; CI)
was 40.3% (29.1–55.1) with PET, 39.2% (26.7–49.4) with
CT, and 100% (90.5–100) with EUS–FNA ( p< 0.001 for
EUS–FNA compared with either PET or CT). Accuracy was
also significantly better with EUS–FNA ( p< 0.001).
Importantly, the investigators determined that, conserva-
tively, 57% of the patients avoided surgery to determine
their lymph node status. Also of note is the fact that, of 37
patients in whom EUS–FNA identified malignant disease,
31% had previously undergone mediastinoscopy that
determined benign disease in the anterior mediastinum.
A more recent minimally invasive technique is
EBUS–TBNA. Exploring almost the same nodal stations
as mediastinoscopy, EBUS–TBNA will surely become
more common in staging the mediastinum. As the
development of real-time ultrasound-guided transbronchial
needle aspiration has become available, more teams use this
technique for the initial sampling of nodal stations 1–5, 7,
10, and 11. Recent publications have shown a sensitivity
of 85–96%, a specificity of 100%, and an accuracy of
89–97%.30–32 The most recent data by Herth et al.33
demonstrated a negative predictive value of 96% (in normal-
sized lymph nodes, based on chest CT). Using such a
minimally invasive technique leaves a clean field, providing
the option, in the event of a negative result, to perform
mediastinoscopy before making a surgical decision.
Whether it would be of interest to add EUS–FNA to this
endobronchial ultrasound staging is probably parallel to the
discussion on cervical mediastinoscopy. EBUS–TBNA and
EUS–FNA have been studied in combination in 33 patients,
with a promising accuracy of 100% for diagnosingCopyright © Adis Data Information BV. Una
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is to be sampled, transbronchial needle aspiration alone has
demonstrated similar sensitivity to the endobronchial
ultrasound-guided technique.35
At present, these data suggest that adding EUS–FNA or
EBUS–TBNA may be particularly useful in preventing
unnecessary thoracotomies by identifying patients who are
truly stage III rather than I or II. Only the presence of N2 or
M1 disease currently alters preoperative decision making. In
the future, however, if neoadjuvant therapy for stages IB and
II become the standard of care, the differences between
clinical and pathological staging and the efficacy of
preoperative staging will become even more important.
INTRAOPERATIVE NODAL STAGING:
DISSECTION VERSUS SAMPLING
No clear consensus exists regarding whether to perform
lymph node sampling or full nodal dissection in resectable
patients. The true value of dissection compared with its
purported risks has not been adequately studied in
prospective studies. Evidence suggests that dissection
does indeed identify N2 disease otherwise missed by
conventional staging and sampling. In 208 patients without
bulky disease who were consecutively resected at three
centers, sampling was performed first followed by full
dissection in each patient.36 A total of 60 patients were
identified as having N2 disease; 31 of these (52%) were
identified with sampling alone. Of those with multilevel N2
disease, sampling only identified 40%. Of the 60 patients
with N2 disease, 24 had skip metastases to the mediastinal
nodes with normal N1 nodes. Although this report did not
specify the clinical compared with pathological stage in
these patients, a switch from stage I to IIIA might, based on
recent evidence with adjuvant chemotherapy, alter the
postoperative treatment plan and affect long-term survival.
Although evidence of a survival benefit from adjuvant
chemotherapy has been difficult to assess, currently
available data demonstrate a potential dichotomy between
stages I and II/III disease. The 1995 meta-analysis that
demonstrated a survival benefit for adjuvant cisplatin-based
chemotherapy in NSCLC37 has been supported by
subsequent randomized trials (Table 5).9,38–41 Nonetheless,
another large trial (Adjuvant Lung Project Italy; ALPI)
failed to demonstrate a survival advantage.42 A meta-
analysis of the five largest recent adjuvant trials of
cisplatin-based adjuvant therapy (Lung Adjuvant Cisplatin
Evaluation; LACE) has helped to clarify the issue and these
results were recently presented.43 Included in this analysis
were individual patient data from the following trials: ALPI,
Adjuvant Navelbine International Trialist Association
(ANITA), Big Lung Trial (BLT), International Adjuvant
Lung Cancer Trial (IALT), and JBR.10. Results demon-
strated an overall hazard ratio (HR) of death of 0.89 (95% CI
0.82–0.96; p< 0.005) with chemotherapy. The absolute
benefit in 5-year survival was 4.2%. The benefit, however,
varied by stage, with the greatest benefit shown in stages II
(HR 0.83; 95% CI 0.73–0.95) and III (HR 0.83; 95% CI
0.73–0.95), and possibly no benefit at all in stage IAuthorized reproduction of this article is prohibited.
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TABLE 5. Adjuvant Chemotherapy in Early-Stage NSCLC: Summary of Selected Phase III Trials.
Study Regimen Stage N
Survival
Median, months 5-Year, %
Kato (2004)39 UFT IA–IB 491 NR 88
Observation 488 NR 85
IALT (2004)38 CDDP-based IA–IIIA 932 50.8 45
Observation 935 44.4 40
JBR.10 (2004)41 Cisplatin/Vinorelbine IB–II 243 94 69
Observation 238 73 54
CALGB 9633 (2004)40 Paclitaxel/Carboplatin IB 173 95 59
Observation 171 78 57
Douillardy (2006)9 Vinorelbine/Cisplatin IB–IIIA 407 65.7 51
Observation 433 43.7 43
NR, Not reported; NRe, not reached.
Statistically significant;
y 7-year: 45 versus 37%.
Kim and Bosque´e Journal of Thoracic Oncology * Volume 2, Number 6, Supplement 2, June 2007(HR 1.41; 95% CI 0.96–2.09). The HR in stage IB was 0.93
(95% CI 0.78–1.10). This meta-analysis suggests a clear
difference between stages II/III and stage I NSCLC in
survival benefit from adjuvant chemotherapy. This differ-
ence highlights the need for accurate pathological staging to
identify appropriate candidates for adjuvant chemotherapy.
The use of lymph node dissection rather than sampling can
improve the accuracy of pathological staging and ultimately
have an important effect on treatment outcomes for
early-stage NSCLC.
Despite the enhanced ability of mediastinal lymph node
dissection to detect N2 disease, and thus appropriately
identify chemotherapy candidates, sampling is frequently
performed instead of dissection because of concerns about
increased postoperative morbidity and mortality with full
dissection. To address these concerns specifically, the
ACOSOG conducted a large randomized prospective trial
(Z0030) that compared the two procedures.44 The primary
objective was to determine whether overall long-term
survival is affected by the choice of procedure. Immediate
postoperative complications and mortality were evaluated as
a secondary objective, and a preliminary report of these
findings was recently published. Patients with clinically
resectable T1–2, N0 or non-hilar N1, M0 NSCLC with no
evidence of mediastinal involvement based on either CT or
mediastinoscopy, if performed, were eligible. All patients
underwent lymph node sampling at the time of resection.
Those with no evidence of cancer upon sampling were
randomly assigned to either sampling only (i.e. no further
dissection) or full lymph node dissection. Lymph node
dissection was performed in 525 patients, whereas sampling
alone was performed in 498 patients. Although dissection
led to slightly increased blood loss ( p¼ 0.033), a median
operative time of 15 min longer ( p< 0.0001), and greater
chest tube drainage ( p¼ 0.056), the duration of hospital-
ization was no different between the groups (median 6 days;
p¼ 0.4). Furthermore, no difference occurred in the rate of
any specific postoperative complication between the groups.Copyright © Adis Data Information BV. Una
S64Postoperative mortality was also not statistically different
between groups (2.0% with sampling versus 0.76% with
dissection; p¼ 0.157). These data show that avoiding
dissection because of potential increases in morbidity and
mortality is not necessary. A previous study suggested that
survival may be improved with dissection.45 With short-
term follow-up, the impact of dissection on long-term
survival in that study is not yet known. Mediastinal lymph
node disease (N2) was, however, discovered in 20 patients
who otherwise had negative sampling (3.8%). These results
corroborate the increased accuracy of dissection and
furthermore prove that the procedure is a safe alternative
to sampling.
RESTAGING AFTER NEOADJUVANT THERAPY
IN STAGE IIIA N2
How to re-stage patients after neoadjuvant therapy has
its own challenges, particularly in patients who have already
undergone mediastinoscopy. Repeating mediastinoscopy
can be difficult because of adhesions and fibrosis resulting
from the initial procedure. In one of the largest studies of
remediastinoscopy after neoadjuvant therapy, the procedure
was not possible in five out of 165 patients (3%) because of
adhesions.46 Although EUS–FNA would be useful, its
availability is still limited. Video-assisted thoracoscopic
surgery (VATS) may be a feasible alternative to remedias-
tinoscopy as suggested by a phase II study by the Cancer and
Leukemia Group B (CALGB).47 Of 70 attempted
procedures, 53 (76%) were successful. The remaining
17 (24%) failed with the majority as a result of adhesions/
fibrosis. CT, PET, or integrated PET–CT are currently the
primary options in this setting.
Recent evidence suggests that integrated PET–CT is
perhaps the most valuable non-invasive tool. The Leuven
Lung Cancer Group compared integrated PET–CT with
remediastinoscopy in 30 patients who underwent preopera-
tive chemotherapy for stage IIIA N2 disease, and were
consecutively resected at a single institution.48 N2 diseaseuthorized reproduction of this article is prohibited.
 2007 International Association for the Study of Lung Cancer
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correctly identified N2 disease in 13 (76%); remediastino-
scopy correctly identified N2 disease in five (29%).
Nevertheless, all teams do not report the same difficulties
with remediastinoscopy as reported by the Leuven Group.
Other groups have reported sensitivity of 70–74%,
specificity of 100%, and accuracy of 80–92.5% with
remediastinoscopy.46,49–51 Positive and negative predictive
values for remediastinoscopy have been reported as 100 and
75–86%.46,50 In practice, however, many surgeons hesitate
to perform a second aggressive look at the mediastinum.
Once again, this difficulty could be avoided if the
initial invasive staging was performed using ultrasound
techniques.
Comparing PET–CT with either PET or CT alone,
PET–CT showed greater sensitivity, specificity, accuracy,
positive predictive value, and negative predictive value than
either of the other two alone in the Leuven Group study.48
Cerfolio and colleagues52 also found integrated PET–CT
superior to CT alone for restaging in a prospective trial of
93 patients with biopsy-confirmed stage IIIA N2 disease.
Of interest in that study was an analysis of the magnitude of
change of maximal SUV in mediastinal nodes on repeat
PET–CT. A reduction in the maximum SUV of a previously
involved N2 node by more than 50% led to a high likelihood
that the node was now benign (positive likelihood ratio 7.9).
The investigators noted, however, that a positive result still
necessitates biopsy as residual cancer may not in fact be
present despite an elevated SUV.
In conclusion, medical oncologists are still faced with
multiple factors to consider when staging each patient and a
lack of the availability of newer procedures remains a
challenge. Identifying pathological N2 disease is, however,
of great importance because its presence significantly
affects outcomes and potential treatment strategies. Recent
data supporting the use of adjuvant or neoadjuvant
therapies in these patients suggest that every reasonable
effort should be made to assess N2 disease accurately in
patients with clinical stage I–II disease, as well as in those
with clinical stage IIIA N2 disease who have undergone
preoperative treatments. Newer procedures such as inte-
grated PET–CT, EUS–FNA and EBUS–TBNA are non
or minimally invasive techniques that may enhance the
accuracy of preoperative or post-therapy mediastinal
staging. As their availability widens, they are likely to
become part of the standard treatment paradigms. Intra-
operatively, a growing body of evidence suggests that
lymph node dissection can be performed safely and should
replace sampling as a more effective means of identifying
unsuspected N2 disease.REFERENCES
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